Skip to main content
Signal8
Launch Terminal

SI-BONE, Inc. (SIBN)

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

SI-BONE, Inc. logo

SI-BONE, Inc.

NASDAQ:SIBNHealthcare
-5.27%$21.23
AH$21.23+0.00%vs close
Mkt Cap$951.5M
Float43.03M
O/S44.82M
Vol
$ Vol
RVOL
Inst Own-
SI10.9%
Earnings
Dilution
SI-BONE, Inc. logoNASDAQ:SIBN$21.23-5.27%
Phase Distribution
13 lead-sponsored trials·4 active·6 completed
Phase 42
Not applicable11
(4 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting1
Active, not recruiting3
Completed6
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Terminated

    Validity and Reliability of Diagnostic Findings of SI Joint Blocking

    0.75% bupivacaine, .75% bupivacaine

    SI Joint Pain

    Enrollment
    28
    Start
    Apr 2013
    Primary Completion
    Sep 2014
    Completion
    Sep 2014
    NCT01874236
  • Phase 4
    Active, not recruiting

    iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction

    Use of iFuse TORQ

    Sacroiliac Joint Dysfunction, Sacroiliac; Fusion +2

    Enrollment
    110
    Start
    May 2023
    Primary Completion
    Apr 2025
    Completion
    Nov 2027est.
    NCT05870488
  • Observational
    Completed

    Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

    -

    Degenerative Sacroiliitis, Sacroiliac Joint Disruption

    Enrollment
    194
    Start
    Jul 2012
    Primary Completion
    Jan 2015
    Completion
    Feb 2016
    NCT01640353
  • Not applicable
    Completed

    Investigation of Sacroiliac Fusion Treatment (INSITE)

    iFuse Implant System, Non-surgical management

    Degenerative Sacroiliitis, Sacroiliac Joint Disruption

    Enrollment
    159
    Start
    Sep 2012
    Primary Completion
    Feb 2015
    Completion
    Jun 2017
    NCT01681004
  • Not applicable
    Completed

    iFuse Implant System® Minimally Invasive Arthrodesis

    iFuse Implant System, Conservative Management

    Sacroiliac Joint Pain

    Enrollment
    103
    Start
    Jun 2013
    Primary Completion
    Dec 2015
    Completion
    Sep 2017
    NCT01741025
  • Observational
    Completed

    LOIS: Long-Term Follow-Up in INSITE/SIFI

    Pelvic CT at 5 years post-op

    Degenerative Sacroilitis, Sacroiliac Joint Disruption

    Enrollment
    103
    Start
    Oct 2014
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT02270203
  • Not applicable
    Completed

    Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants

    SIJ fusion with iFuse-3D

    Sacroiliac Dysfunction

    Enrollment
    51
    Start
    Oct 2017
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT03122899
  • Not applicable
    Completed

    SI Joint Stabilization in Long Fusion to the Pelvis

    iFuse 3-D in Bedrock Configuration, Multilevel Lumbar Fusion surgery

    Sacroiliac Joint Disruption, Scoliosis Lumbar Region

    Enrollment
    213
    Start
    May 2020
    Primary Completion
    Dec 2024
    Completion
    Jan 2025
    NCT04062630
  • Not applicable
    Terminated

    Sacral Fracture Fusion/Fixation for Rapid Rehabilitation

    Surgical Intervention, Non-Surgical Management

    Fracture;Pelvis, Sacral Fracture +4

    Enrollment
    28
    Start
    Sep 2022
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05426356
  • Observational
    Active, not recruiting

    Pelvic Fixation and Fusion During Multilevel Spinal Surgery

    iFuse Bedrock Granite Implant System

    Spinal Fusion, Deformity of Spine

    Enrollment
    200
    Start
    Jun 2023
    Primary Completion
    Nov 2027est.
    Completion
    Dec 2027est.
    NCT05640908
  • Observational
    Active, not recruiting

    Innovative Spinopelvic Solutions With Real-World Evidence

    Health questionnaires

    Sacroiliac Joint Dysfunction, Sacroiliac Joint Pain

    Enrollment
    1,000
    Start
    Dec 2024
    Primary Completion
    Dec 2034est.
    Completion
    Dec 2034est.
    NCT06706908
  • Observational
    Recruiting

    Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures

    iFuse TORQ TNT Implant System

    Fracture; Pelvic, Insufficiency Fractures +4

    Enrollment
    120
    Start
    Aug 2026est.
    Primary Completion
    Feb 2028est.
    Completion
    Aug 2028est.
    NCT07530497
  • Observational
    Not yet recruiting

    Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes

    iFuse INTRA Ti Implant System

    Sacro Iliac Joint Pain, Sacro-iliac Joints +4

    Enrollment
    120
    Start
    Sep 2026est.
    Primary Completion
    Mar 2028est.
    Completion
    Sep 2029est.
    NCT07565545
Search ClinicalTrials.gov for “Si-Bone”